Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Maximum doses of proton pump inhibitors in hepatic impairment
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty)
- Co-author(s): Andreia Primo: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
Inês Martins: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
Luís Caetano: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
Nuno Pereira: Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal
Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
Manuel Morgado: Higher School of Health, Portuguese Pharmaceutical Society, Guarda, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal;Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal
BackgroundSome of the most commonly used drugs, including most proton pump inhibitors (PPIs) are eliminated by the hepatic route. If liver function is impaired, it can be anticipated that hepatic clearance will be delayed, which can lead to more pronounced drug accumulation.
MethodsThe databases of the Nacional Authority of Medicines and Health.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019